ClinicalTrials.gg
CompletedNCT03948698TIPPIUpdated Apr 18, 2023Results posted

TB Innovation Project: A Pre- and Post- Implementation Assessment (TIPPI)

An observational study in Tuberculosis and Pediatric, sponsored by Elizabeth Glaser Pediatric AIDS Foundation. Completed at 10 sites in 10 countries. Open to participants aged Up to 14 Years. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Elizabeth Glaser Pediatric AIDS Foundation · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
4,159,533
Ages
Up to 14 Years
Sex
All
01

Study summary

This evaluation will be conducted in ten countries involved in the Catalyzing Pediatric TB Innovation (CaP-TB) project: Cameroon, Cote D'Ivoire, Democratic Republic of Congo, Kenya, Lesotho, Malawi, Tanzania, Uganda, Zimbabwe and India. The CaP-TB project is a project designed to use innovative methods and capacity building to strengthen the health systems of developing countries in terms of pediatric TB case detection, early accurate diagnosis and effective treatment. This project is funded by Unitaid and is implemented by Elizabeth Glaser Pediatric AIDS Foundation.

EGPAF proposes to evaluate the implementation of CaP-TB in up to 450 sites in ten participating countries. This evaluation will assess the effects of CaP-TB innovative interventions on selected service delivery outcomes as compared to routine TB program in a sub-set of project sites in the ten countries.

Read the detailed description

This pre-post quasi-experimental evaluation study will be conducted in ten countries involved in the Catalyzing Pediatric TB Innovation (CaP-TB) project: Cameroon, Cote D'Ivoire, Democratic Republic of Congo, Kenya, Lesotho, Malawi, Tanzania, Uganda, Zimbabwe and India. The CaP-TB project is a project designed to use innovative methods and capacity building to strengthen the health systems of developing countries in terms of pediatric TB case detection, early accurate diagnosis and effective treatment. This project is funded by Unitaid headquartered in Geneva, Switzerland and is implemented by Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) with headquarters in Washington, D.C. and Geneva and 10 country offices. This study will assess the effects of CaP-TB innovative interventions on selected service delivery outcomes as compared to routine TB program in a sub-set of project sites in ten countries.

The CaP TB project is a 4-year (October 1, 2017-September 30, 2021) Unitaid-funded project to improve pediatric TB outcomes by introducing integrated and decentralized models of pediatric TB care and strengthening access to WHO-recommended drugs and diagnostics. Integration refers to supporting TB activities, such as screening and TB sample collection for children, into non-TB health care services, such as general pediatric outpatient clinics. Decentralization refers to moving pediatric TB services from higher levels of health clinics to lower levels.

Objectives of the study

To evaluate the CaP TB project on the below TB service indicators and clinical outcomes for children 0-14 in facilities implementing the CaP TB project:

  • Number and proportion of children screened for TB among clinic attendees
  • Number and proportion of presumptive TB cases referred for lab-based TB diagnosis
  • Number and proportion of pediatric presumptive TB cases who are tested with Xpert
  • Number and proportion (out of all children screened) of pediatric cases diagnosed with active TB disease
  • Time between when a child is identified as a presumptive TB case and when the child is diagnosed with TB
  • Number and proportion of pediatric TB cases started on DS-TB treatment
  • Time between when a child is identified as a presumptive TB case and when the child is initiated on TB treatment
  • Number and proportion of pediatric DS-TB cases or cases treated with first-line TB treatment who achieve treatment success
  • Number and proportion of all TB index cases for whom successful contact tracing has been done
  • Number and proportion of pediatric household contacts who are negative to TB screening

Study data

Pre-intervention retrospective data collection

Under the standard of care condition (baseline), the investigators will:

  • Capture data that will answer the TB service indicators and clinical outcomes listed in the primary objectives.
  • Capture key data points that will be needed to estimate project targets In each site, trained data collectors will retrospectively extract data from appropriate registers, logs, and in some cases patient files, for a period of 12 months starting 6 months before the start date of data extraction.

After the implementation of the CaP TB project, prospective data will be collected by project-specific data collection tools and/or from existing registers. Whenever possible, the CaP TB data collection will use existing site level data collection tools to gather the data for the project.

02

Conditions studied

  • Tuberculosis
  • Pediatric

Browse trials for

03

In context

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

This study's enrollment of 4,159,533 is above the median of 253 across 317 observational studies indexed under Tuberculosis.

Browse Tuberculosis studies →

Lead sponsor

Elizabeth Glaser Pediatric AIDS Foundation is the lead sponsor of 30 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 14 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All pediatric TB patients (0-14 years of age) who present to a CaP TB project site in any of the 10 countries and receive TB services (including screening, diagnosis and treatment for active TB, and provision of TB preventive therapy).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10 countries and receive TB screening (including screening, diagnosis and treatment for active TB, and provision of TB preventive therapy).
  • All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10 countries and receive TB diagnosis
  • All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10 countries and receive TB treatment for active TB
  • All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10 countries and receive TB preventive therapy

Exclusion criteria

Exclusion Criteria:

  • All pediatric TB patients who enter CaP TB project site in any of the 10 countries and who are above 15 years old
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
4,159,533 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • OtherInnovative approached to pediatric TB care

    Includes integration of TB care in non-TB entry points in facilities, decentralization from higher level clinics to lower levels, strengthening screening activities and building diagnosis and treatment capacity among healthcare workers

    Also known as: Integration and decentralization

06

What researchers measure

Primary outcomes

  1. Children Screened for TB

    Number and proportion of children (age 0-14) screened for TB among clinic attendees

    Time frame: December 2018-September 2021

  2. Children With Presumptive TB

    Among those screened the number and proportion of children presumed to have TB.

    Time frame: December 2018-September 2021

  3. Children With Presumptive TB Referred for Lab-based TB Diagnosis

    Number and proportion of presumptive TB cases referred for lab-based TB diagnosis

    Time frame: December 2018-September 2021

  4. Children With Presumptive TB Tested Using GeneXpert

    Number and proportion of pediatric (0-14 years) presumptive TB cases who are tested with GeneXpert

    Time frame: December 2018-September 2021

  5. Children Initiated on TB Preventive Therapy

    Number and proportion of pediatric patients started on preventive therapy of those who are eligible for preventive therapy

    Time frame: December 2018-September 2021

  6. Children Completing TB Preventive Therapy

    Number and proportion of pediatric patients on preventive treatment who completed therapy

    Time frame: December 2018-September 2021

  7. Children Diagnosed With Active TB

    Number of pediatric cases diagnosed with active TB disease among children with presumptive TB

    Time frame: December 2018-September 2021

  8. Children Initiated on TB Treatment

    Number and proportion of pediatric TB cases started on DS-TB treatment

    Time frame: December 2018-September 2021

  9. Children Achieving Treatment Success

    Number and proportion of pediatric DS-TB cases who achieve treatment success

    Time frame: December 2018-September 2021

  10. TB Contacts Successfully Traced

    Number and proportion of all TB index cases for whom successful contact tracing has been done

    Time frame: December 2018-September 2021

  11. TB Contacts Screened Negative for TB

    Number and proportion of pediatric household contacts who are negative to TB screening

    Time frame: December 2018-September 2021

  12. TB Contacts Eligible for Preventive Therapy

    Number and proportion of screened negative pediatric contacts eligible for preventive therapy

    Time frame: December 2018-September 2021

07

Results

Posted Dec 20, 2021

Participant flow

Participant flow — Overall Study
MilestoneCaP TB TIPPI Study
Started4749072
Completed4749072
Not completed0

Outcome measures

PrimaryChildren Screened for TB

Number and proportion of children (age 0-14) screened for TB among clinic attendees

Time frame:
December 2018-September 2021
Reported as:
Count of participants · Participants
Children Screened for TB
ParticipantsCaP TB TIPPI Study
Children Screened for TB4749072
PrimaryChildren With Presumptive TB

Among those screened the number and proportion of children presumed to have TB.

Time frame:
December 2018-September 2021
Reported as:
Count of participants · Participants
Children With Presumptive TB
ParticipantsCaP TB TIPPI Study
Children With Presumptive TB60250
PrimaryChildren With Presumptive TB Referred for Lab-based TB Diagnosis

Number and proportion of presumptive TB cases referred for lab-based TB diagnosis

Time frame:
December 2018-September 2021
Reported as:
Count of participants · Participants
Children With Presumptive TB Referred for Lab-based TB Diagnosis
ParticipantsCaP TB TIPPI Study
Children With Presumptive TB Referred for Lab-based TB Diagnosis49022
PrimaryChildren With Presumptive TB Tested Using GeneXpert

Number and proportion of pediatric (0-14 years) presumptive TB cases who are tested with GeneXpert

Time frame:
December 2018-September 2021
Reported as:
Count of participants · Participants
Children With Presumptive TB Tested Using GeneXpert
ParticipantsCaP TB TIPPI Study
Children With Presumptive TB Tested Using GeneXpert35554
PrimaryChildren Initiated on TB Preventive Therapy

Number and proportion of pediatric patients started on preventive therapy of those who are eligible for preventive therapy

Time frame:
December 2018-September 2021
Reported as:
Count of participants · Participants
Children Initiated on TB Preventive Therapy
ParticipantsCaP TB TIPPI Study
Children Initiated on TB Preventive Therapy28762
PrimaryChildren Completing TB Preventive Therapy

Number and proportion of pediatric patients on preventive treatment who completed therapy

Time frame:
December 2018-September 2021
Reported as:
Count of participants · Participants
Children Completing TB Preventive Therapy
ParticipantsCaP TB TIPPI Study
Children Completing TB Preventive Therapy22590
PrimaryChildren Diagnosed With Active TB

Number of pediatric cases diagnosed with active TB disease among children with presumptive TB

Time frame:
December 2018-September 2021
Reported as:
Count of participants · Participants
Children Diagnosed With Active TB
ParticipantsCaP TB TIPPI Study
Children Diagnosed With Active TB11078
PrimaryChildren Initiated on TB Treatment

Number and proportion of pediatric TB cases started on DS-TB treatment

Time frame:
December 2018-September 2021
Reported as:
Count of participants · Participants
Children Initiated on TB Treatment
ParticipantsCaP TB TIPPI Study
Children Initiated on TB Treatment10834
PrimaryChildren Achieving Treatment Success

Number and proportion of pediatric DS-TB cases who achieve treatment success

Time frame:
December 2018-September 2021
Reported as:
Count of participants · Participants
Children Achieving Treatment Success
ParticipantsCaP TB TIPPI Study
Children Achieving Treatment Success6553
PrimaryTB Contacts Successfully Traced

Number and proportion of all TB index cases for whom successful contact tracing has been done

Time frame:
December 2018-September 2021
Reported as:
Count of participants · Participants
TB Contacts Successfully Traced
ParticipantsCaP TB TIPPI Study
TB Contacts Successfully Traced20998
PrimaryTB Contacts Screened Negative for TB

Number and proportion of pediatric household contacts who are negative to TB screening

Time frame:
December 2018-September 2021
Reported as:
Count of participants · Participants
TB Contacts Screened Negative for TB
ParticipantsCaP TB TIPPI Study
TB Contacts Screened Negative for TB37774
PrimaryTB Contacts Eligible for Preventive Therapy

Number and proportion of screened negative pediatric contacts eligible for preventive therapy

Time frame:
December 2018-September 2021
Reported as:
Count of participants · Participants
TB Contacts Eligible for Preventive Therapy
ParticipantsCaP TB TIPPI Study
TB Contacts Eligible for Preventive Therapy19630

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CaP TB TIPPI Study———

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CaP TB TIPPI Study
<=18 years2318
Between 18 and 65 years0
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)CaP TB TIPPI Study
Female1163
Male1155
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)CaP TB TIPPI Study
Region of Enrollment
Region of Enrollment(participants)CaP TB TIPPI Study
Cameroon159
Malawi167
Côte D'Ivoire247
Congo, The Democratic Republic of the709
Tanzania335
Uganda92
Zimbabwe281
Kenya212
Lesotho116
08

Study locations

10 sites
  • Sites in Centre, Littoral and West regions
    Djoungolo, Cameroon
  • Bandalungwa,Binza Meteo,Kikimi,Kingasani,Kinshasa, Lingwala, Masina II, Mont Ngafula II, Ndjili
    Kinshasa, Congo, The Democratic Republic of the
  • Adjame-Plateau-Attecoube, Abobo Est,Anyama , Koumassi-Port Bouet-Vridi, Treichville-Marcory
    Abidjan, Côte D'Ivoire
  • Sites in Maharashtra State, Telangana State, Andhra Pradesh
    Hyderabad, India
  • Turkana County and Homabay County sites
    Nairobi, Kenya
  • Berea, Maseru, Mageteng, Leribe, Mohale's Hoek sites
    Maseru, Lesotho
  • Central Region, Southern region sites
    Dedza, Malawi
  • Singida, Tabora sites
    Singida, Tanzania
  • Mbarara sites
    Mbarara, Uganda
  • Harare, Manicaland, Matabeleland South
    Harare, Zimbabwe
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03948698
Lead sponsor
Elizabeth Glaser Pediatric AIDS Foundation
Responsible party
Sponsor
First posted
May 14, 2019
Start date
Dec 1, 2018
Primary completion
Sep 30, 2021
Completion
Sep 30, 2021
Results posted
Dec 20, 2021
Last update
Apr 18, 2023

Study contacts

Jennifer Cohn, MD
principal investigator · Elizabeth Glaser Pediatric AIDS Foundation
Martina Casenghi, PhD
principal investigator · Elizabeth Glaser Pediatric AIDS Foundation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion